Skip to main
MYNZ
MYNZ logo

MYNZ Stock Forecast & Price Target

MYNZ Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mainz Biomed NV has demonstrated a robust growth trajectory, with total revenue increasing approximately 88% year-over-year to $181.7 thousand, reflecting successful penetration into the German market and ongoing expansion in Romania and Poland. The company's investment in research and development, which saw a 104% increase to $1.9 million, is aimed at enhancing the accuracy of its flagship product, ColoAlert, evidenced by improved sensitivity and specificity in colorectal cancer detection. Additionally, positive results from recent studies, including the European ColoFuture trial, underscore the promising efficacy of integrating novel biomarkers into ColoAlert, reinforcing the company's potential in the molecular diagnostics space.

Bears say

Mainz Biomed NV is facing a negative outlook primarily due to significantly lowered revenue estimates for 2023 and 2024, which are now projected at $0.9 million and $3.5 million, respectively, as a result of slower market penetration in Germany and difficulties in expanding to new geographies. Additionally, the company is grappling with liquidity and balance sheet concerns, leading to a lack of visibility regarding its near-term financial performance and the expectation of needing additional capital that could dilute existing shareholders. Compounded by a highly competitive market landscape and commercialization risks, particularly related to the ColoAlert test’s potential failure to secure regulatory approval in the U.S. and its ability to achieve market adoption, Mainz Biomed's financial stability is under significant pressure.

MYNZ has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mainz Biomed BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mainz Biomed BV (MYNZ) Forecast

Analysts have given MYNZ a Strong Buy based on their latest research and market trends.

According to 4 analysts, MYNZ has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mainz Biomed BV (MYNZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.